Profile photo

Lung Cancers With Coral Olazagasti, MD

Oncology / Hematology

Dr. Coral Olazagasti is a medical oncologist and Assistant Professor at the Sylvester Comprehensive Cancer Center, University of Miami. She specializes in head and neck as well as thoracic malignancies. Dr. Olazagasti earned her medical degree from the Universidad Central del Caribe in Bayamón, Puerto Rico.

IMforte Trial Delivers Long-Awaited Breakthrough in Maintenance Therapy

Dear readers,

At this year’s ASCO Annual Meeting, the IMforte trial delivered what the small cell lung cancer (SCLC) community has long awaited: a breakthrough in maintenance therapy. This Phase 3 trial compared atezolizumab (Atezo) plus lurbinectedin vs. Atezo alone as maintenance therapy in patients with extensive-stage SCLC following initial platinum-based chemotherapy. The study revealed a median progression free survival  of 5.4 months vs 2.1 with atezo alone. More importantly, there was an observed overall survival benefit with the combination arm of 13.2 months versus 10.6 months. Despite decades of research, SCLC has remained one of the most treatment-refractory malignancies with few advances in the maintenance setting. IMforte offers a real, actionable step forward and provides  a practice-changing option that clinicians can offer with confidence and optimism.

Sincerely,
Coral Olazagasti, MD

Articles
  • Mashup Score: 34
    • Profile photo of BalazsHalmosMD
      BalazsHalmosMD

      IMForte trial of atezo+- lurbinectidine for pts w ES-SCLC (note no CNS disease)

      Expected PFS and (as pleasant surprise) quite notable OS benefit linked w fair toxicity/ easy implementation makes me believe that this regimen will immediately Jazz up the ES-SCLC landscape as the https://t.co/VE65Oydfvm

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 48
    • Profile photo of RManochakian
      RManochakian

      🔥🚨@OncoAlert Hot Off The Press

      Just presented @ASCO #ASCO25 by the amazing @LuisPaz_Ares

      ✅Results of #IMforte trial of:

      #Lurbinectedin + #Atezolizumab as 1st line #Maintenance Tx in #Patients
      with #ExtensiveStage #SmallCell #LungCancer.

      👇🏻 https://t.co/UQqAy3LsDv

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 22
    • Profile photo of Latinamd
      Latinamd

      #ASCO25 🫁Lung Cancer Orals:

      #IMforte Ph3 Maintenance #Lurbinectedin+ Atezolizumab in ES- SCLC

      🎙️@LuisPaz_Ares

      🔹PFS 5.4 vs 2.1 mos (HR 0.54)
      🔹mOS from randomized 13.2 vs 10.6m (HR 0.57)
      ⬆️ AEs Hematological

      👉🏽New SOC 1L maintenance lurbi+atezo for ES-SCLC (at some extra https://t.co/Z281iCLeLw

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 42
    • Profile photo of GlopesMd
      GlopesMd

      As @ASCO #ASCO25 abstracts come out let’s discuss the ones that are creating new options for our patients

      #IMforte trial – we knew it was positive given the press release, but it is great to see the actual numbers. Not quite a home run but certainly significant and establishes a https://t.co/LFS5zMMjpQ

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 15
    • Profile photo of CharuAggarwalMD
      CharuAggarwalMD

      Small cell lung cancer (SCLC) continues to pose challenges — looking forward to new therapeutic strategies presented at #ASCO25

      #IMForte – generating a lot of buzz, and looking forward to the data! #SCLC

      @PennMDForum @PennMedicine @PennCancer @ASCO @OncoAlert

      Read the original tweet here

    Tweet Tweets with this article